Quick Answer
ELITE PHARMACEUTICALS INC /NV/ reported R&D Expense of $7.96 million for fiscal year 2025.
ELITE PHARMACEUTICALS INC /NV/ R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $7.96M | +15.7% |
| 2024 | $6.88M | +11.0% |
| 2023 | $6.20M | +53.0% |
| 2022 | $4.05M | -20.8% |
| 2021 | $5.11M | -7.6% |
| 2020 | $5.53M | -27.2% |
| 2019 | $7.60M | -21.0% |
| 2018 | $9.62M | +15.9% |
| 2017 | $8.30M | -33.2% |
| 2016 | $12.43M | -15.6% |
| 2015 | $14.73M | +272.0% |
| 2014 | $3.96M | +306.0% |
| 2013 | $975.2K | -43.8% |
| 2012 | $1.74M | +25.3% |
| 2011 | $1.39M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $1.04M | -42.0% | -24.9% |
| September 30, 2025 | $1.39M | -29.5% | -17.3% |
| June 30, 2025 | $1.67M | -22.6% | -6.6% |
| December 31, 2024 | $1.79M | +27.8% | -8.8% |
| September 30, 2024 | $1.97M | -24.9% | -9.1% |
| June 30, 2024 | $2.16M | +89.2% | +54.1% |
| December 31, 2023 | $1.40M | -2.7% | -46.4% |
| September 30, 2023 | $2.62M | +113.3% | +129.0% |
- ELITE PHARMACEUTICALS INC /NV/ showed an increase of +15.7% in R&D Expense compared to the prior fiscal year.
- Over the 2011–2025 period, ELITE PHARMACEUTICALS INC /NV/’s r&d expense has grown by 475.0% (from $1.39 million to $7.96 million).
- The most recent figure is from ELITE PHARMACEUTICALS INC /NV/’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 30, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: